AU2012328561A1 - Benzoxazolinone compounds with selective activity in voltage-gated sodium channels - Google Patents
Benzoxazolinone compounds with selective activity in voltage-gated sodium channels Download PDFInfo
- Publication number
- AU2012328561A1 AU2012328561A1 AU2012328561A AU2012328561A AU2012328561A1 AU 2012328561 A1 AU2012328561 A1 AU 2012328561A1 AU 2012328561 A AU2012328561 A AU 2012328561A AU 2012328561 A AU2012328561 A AU 2012328561A AU 2012328561 A1 AU2012328561 A1 AU 2012328561A1
- Authority
- AU
- Australia
- Prior art keywords
- oxo
- thiadiazol
- dihydro
- sulfonamide
- benzoxazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552885P | 2011-10-28 | 2011-10-28 | |
| US61/552,885 | 2011-10-28 | ||
| PCT/US2012/062207 WO2013063459A1 (en) | 2011-10-28 | 2012-10-26 | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012328561A1 true AU2012328561A1 (en) | 2014-04-17 |
| AU2012328561A8 AU2012328561A8 (en) | 2014-05-01 |
Family
ID=48168585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012328561A Abandoned AU2012328561A1 (en) | 2011-10-28 | 2012-10-26 | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9273040B2 (enExample) |
| EP (1) | EP2770995B1 (enExample) |
| JP (1) | JP2014532660A (enExample) |
| KR (1) | KR20140095067A (enExample) |
| CN (1) | CN103889419A (enExample) |
| AU (1) | AU2012328561A1 (enExample) |
| BR (1) | BR112014010197A2 (enExample) |
| CA (1) | CA2852796A1 (enExample) |
| IN (1) | IN2014CN02959A (enExample) |
| MX (1) | MX2014005068A (enExample) |
| RU (1) | RU2014121489A (enExample) |
| WO (1) | WO2013063459A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9630929B2 (en) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| RU2014121983A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств |
| US8952169B2 (en) | 2012-05-22 | 2015-02-10 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
| CN104797555B (zh) | 2012-07-06 | 2017-12-22 | 基因泰克公司 | N‑取代的苯甲酰胺及其使用方法 |
| HK1213476A1 (zh) | 2013-03-14 | 2016-07-08 | 基因泰克公司 | 取代的三唑並吡啶及其使用方法 |
| CA2898680A1 (en) | 2013-03-15 | 2014-09-18 | Genentech,Inc. | Substituted benzoxazoles and methods of use thereof |
| CA2931732A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| EP3126360A1 (en) | 2014-03-29 | 2017-02-08 | Lupin Limited | Sulfonamide compounds as voltage gated sodium channel modulators |
| WO2016007534A1 (en) | 2014-07-07 | 2016-01-14 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| BR112017018755B1 (pt) * | 2015-03-02 | 2023-05-02 | Amgen Inc | Compostos bicíclicos de cetona sulfonamida e composição farmacêutica relacionada |
| PE20180575A1 (es) | 2015-05-22 | 2018-04-04 | Genentech Inc | Benzamidas sustituidas y metodos para utilizarlas |
| MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
| BR112018006189A2 (pt) | 2015-09-28 | 2018-10-09 | Genentech Inc | compostos da fórmula, composição farmacêutica, métodos de tratamento de uma doença, de diminuição do fluxo de íons e de tratamento de prurido em um mamífero, método para tratamento de dores em um mamífero e uso de um composto |
| JP2018535234A (ja) | 2015-11-25 | 2018-11-29 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル遮断薬として有用な置換ベンズアミド |
| EP3390374B1 (en) | 2015-12-18 | 2020-08-26 | Merck Sharp & Dohme Corp. | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| CN109071426A (zh) | 2016-03-30 | 2018-12-21 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
| CA3023465C (en) | 2016-05-20 | 2024-09-24 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| WO2018072602A1 (en) | 2016-10-17 | 2018-04-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| AU2017371674B2 (en) | 2016-12-09 | 2021-07-22 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体 |
| UY37729A (es) * | 2017-05-11 | 2019-01-02 | Glaxosmithkline Ip Dev Ltd | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 |
| EP3759098A1 (en) | 2018-02-26 | 2021-01-06 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
| US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| US11512072B2 (en) | 2018-04-19 | 2022-11-29 | University Of Virginia Patent Foundation | Compositions and methods for preparing and using azetidines |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| CN112262142B (zh) | 2018-06-13 | 2023-11-14 | 泽农医药公司 | 苯磺酰胺化合物及其作为治疗剂的用途 |
| MA53489A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques |
| US10752623B2 (en) | 2018-08-31 | 2020-08-25 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09124620A (ja) * | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
| CN1177831C (zh) * | 1998-12-04 | 2004-12-01 | 神经研究公司 | 作为离子通道调节剂的新的苯并咪唑啉酮一、苯并噁唑酮一或苯并噻唑啉酮衍生物 |
| CZ20032850A3 (cs) * | 2001-04-18 | 2004-02-18 | Euro-Celtique, S. A. | Analogy nociceptinu |
| EP1467986A1 (en) * | 2002-01-17 | 2004-10-20 | Eli Lilly And Company | Aza-cyclic compounds as modulators of acetylcholine receptors |
| JP2008540539A (ja) * | 2005-05-10 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャンネルの調節因子としての二環系誘導体 |
| KR20080019693A (ko) * | 2005-06-09 | 2008-03-04 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 인단 유도체 |
| CA2633653A1 (en) * | 2005-12-21 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| EP2173743A2 (en) | 2007-07-13 | 2010-04-14 | Icagen, Inc. | Sodium channel inhibitors |
| CA2734651A1 (en) * | 2008-08-21 | 2010-02-25 | Richter Gedeon Nyrt. | Methods for treating neuropathic pain |
| GEP20135992B (en) | 2009-01-12 | 2013-12-25 | Icagen Inc | Sulfonamide derivatives |
| PL2427441T3 (pl) * | 2009-05-04 | 2017-06-30 | Agios Pharmaceuticals, Inc. | Aktywatory PKM2 do stosowania w leczeniu raka |
-
2012
- 2012-10-26 KR KR1020147013911A patent/KR20140095067A/ko not_active Withdrawn
- 2012-10-26 US US14/353,488 patent/US9273040B2/en active Active
- 2012-10-26 WO PCT/US2012/062207 patent/WO2013063459A1/en not_active Ceased
- 2012-10-26 JP JP2014539066A patent/JP2014532660A/ja active Pending
- 2012-10-26 BR BR112014010197A patent/BR112014010197A2/pt not_active IP Right Cessation
- 2012-10-26 MX MX2014005068A patent/MX2014005068A/es not_active Application Discontinuation
- 2012-10-26 CA CA2852796A patent/CA2852796A1/en not_active Abandoned
- 2012-10-26 EP EP12843015.4A patent/EP2770995B1/en not_active Not-in-force
- 2012-10-26 IN IN2959CHN2014 patent/IN2014CN02959A/en unknown
- 2012-10-26 RU RU2014121489/04A patent/RU2014121489A/ru not_active Application Discontinuation
- 2012-10-26 CN CN201280052937.2A patent/CN103889419A/zh active Pending
- 2012-10-26 AU AU2012328561A patent/AU2012328561A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103889419A (zh) | 2014-06-25 |
| CA2852796A1 (en) | 2013-05-02 |
| EP2770995A1 (en) | 2014-09-03 |
| US20140303143A1 (en) | 2014-10-09 |
| BR112014010197A2 (pt) | 2017-04-18 |
| US9273040B2 (en) | 2016-03-01 |
| RU2014121489A (ru) | 2015-12-10 |
| IN2014CN02959A (enExample) | 2015-07-03 |
| EP2770995A4 (en) | 2015-06-03 |
| KR20140095067A (ko) | 2014-07-31 |
| AU2012328561A8 (en) | 2014-05-01 |
| JP2014532660A (ja) | 2014-12-08 |
| EP2770995B1 (en) | 2019-01-02 |
| WO2013063459A1 (en) | 2013-05-02 |
| MX2014005068A (es) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2770995B1 (en) | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels | |
| US9624208B2 (en) | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels | |
| EP3268006B1 (en) | Pyrrolotriazine inhibitors of irak4 activity | |
| EP3267996B1 (en) | Pyrazolopyrimidine inhibitors of irak4 activity | |
| EP3468960B1 (en) | Chemical compounds as atf4 pathway inhibitors | |
| EP2911663B1 (en) | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels | |
| EP3074402B1 (en) | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels | |
| JP2020530446A (ja) | 化合物、組成物、及び、方法 | |
| KR102408272B1 (ko) | 베타-3 아드레날린성 수용체와 관련된 장애의 치료 또는 예방에 유용한 베타-3 아드레날린성 수용체의 조정제 | |
| CA2988147A1 (en) | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders | |
| CA3038756A1 (en) | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors | |
| EP4423068B1 (en) | Rxfp1 agonists | |
| CA3074059A1 (en) | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | |
| CA3001649C (en) | Dopamine d3 receptor antagonists having a morpholine moiety | |
| CA3199269A1 (en) | Isoxazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
| KR20230007441A (ko) | 페로포르틴 억제제로서의 시클로알킬 피리미딘 | |
| JP2008504332A (ja) | ドーパミンｄ３受容体に対してアフィニティーを有する化合物およびその医薬における使用 | |
| WO2025133915A1 (en) | Compounds which bind to pnpla3i148m and their use to treat liver diseases | |
| EA048667B1 (ru) | Циклоалкилпиримидины как ингибиторы ферропортина | |
| NZ786241A (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| NZ615014B2 (en) | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 28 , NO 15 , PAGE(S) 2059 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME MERCK SHARP & DOHME CORP, APPLICATION NO.2012328561, UNDER INID (72) CORRECT THE CO-INVENTOR TO MULHEARN, JAMES |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |